Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

INDUSTRY 3NIH 2OTHER 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2CNS 1

Conditions

Adenomatous Polyposis Coli 2Glioma 1Colonic Polyps 1Brain Neoplasms 1Astrocytoma 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Eflornithine × Clear all
NCT02796261 2022-01-21

STELLAR

Orbus Therapeutics, Inc.

Phase 3 Unknown
343 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioma

NCT01483144 2021-06-08

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Cancer Prevention Pharmaceuticals, Inc.

Phase 3 Completed
171 enrolled 13 charts
Gastrointestinal

Adenomatous Polyposis Coli

NCT01245816 2015-04-24

A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

Cancer Prevention Pharmaceuticals, Inc.

Phase 3 Withdrawn
Gastrointestinal

Colonic Polyps, Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡